SCHEMBL12149488

SCHEMBL12149488

NC(=O)c1ncn([C@@H]2O[C@H](O)[C@@H](O)[C@H]2O)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.75
▸ ALDH1A1 P00352 3/20 0.75
▸ ADORA1 P30542 2/20 0.75
▸ TSHR P16473 2/20 0.75
▸ THPO P40225 2/20 0.75
▸ PMP22 Q01453 2/20 0.75
▸ GLA P06280 1/20 0.75
▸ EIF4E P06730 1/20 0.75
▸ CYP3A4 P08684 1/20 0.75
▸ TOP1 P11387 1/20 0.75
▸ PNP P00491 3/20 0.56
▸ HTR2C P28335 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ TMEM97 Q5BJF2 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ BLM P54132 2/20 0.39
▸ TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12149489 1.00 LMNA (0.75) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL2631654 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL6027558 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL326516 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL3727 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL2619251 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL12658449 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL21311208 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL20806078 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
Ribavirin SCHEMBL4064991 0.86 LMNA (1.00) LMNASMN1; SMN2ALDH1A1ADORA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 — — US disclosed
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 — — US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 — — US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 — — US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 — — US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 — — US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 — — US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 — — US disclosed
US-8022083-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2011-09-20 — — US disclosed
US-8022083-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2011-09-20 — — US disclosed
US-20110071101-A1 Nucleoside Phosphonate Analogs BOOJAMRA CONSTANTINE G 2011-03-24 — — US disclosed
US-7645747-B2 Improved pharmacokinetic properties, oral bioavailability; side effect reduction GILEAD SCIENCES, INC. (US) 2010-01-12 — — US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 — — US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 — — US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 — — US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ALDH1A1 4754/4885
US-20110071101-A1 Nucleoside Phosphonate Analogs TYMP, PNP, NUDT1 LMNA 1265/4885SMN1; SMN2 1122/4885ALDH1A1 3413/4885
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ALDH1A1 4754/4885
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP LMNA 2918/4885SMN1; SMN2 2517/4885ALDH1A1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback